Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops innovative medicines to address serious unmet medical needs. It develops a platform that permits precise characterization of protein interactions in living cells. Its products includes EIK1001 is a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004 are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004, to address brain metastases and primary brain malignancies; EIK1005 a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006. The company was incorporated in 2019 and is based in Millbrae, California.
—
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops innovative medicines to address serious unmet medical needs. It develops a platform that permits precise characterization of protein interactions in living cells. Its products includes EIK1001 is a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004 are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004, to address brain metastases and primary brain malignancies; EIK1005 a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006. The company was incorporated in 2019 and is based in Millbrae, California.
—
Daily adjusted close
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops innovative medicines to address serious unmet medical needs. It develops a platform that permits precise characterization of protein interactions in living cells. Its products includes EIK1001 is a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004 are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004, to address brain metastases and primary brain malignancies; EIK1005 a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006. The company was incorporated in 2019 and is based in Millbrae, California.